Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
Alexander van Akkooi MD, PhD, FRACS
Alexander C. J. van Akkooi MD, PhD, FRACS Associate Editor
Jean-Yves Douillard MD, PhD
Jean-Yves Douillard MD, PhD Advisory Board
Roxana Dronca MD
Roxana S. Dronca MD Advisory Board
See All Experts
story of the week
Published in Oncology

Journal Scan / Research · August 27, 2020

Dabrafenib Plus Trametinib in Patients With BRAFV600E-Mutated Biliary Tract Cancer

The Lancet Oncology

 

 Save  Recommend
 Share

Additional Info

Disclosure statements are available on the authors' profiles:

Axel Grothey MD

Paul Hampel MD

The Lancet Oncology
Dabrafenib Plus Trametinib in Patients With BRAFV600E-Mutated Biliary Tract Cancer (ROAR): A Phase 2, Open-Label, Single-Arm, Multicentre Basket Trial
Lancet Oncol 2020 Aug 17;[EPub Ahead of Print], V Subbiah, U Lassen, E Élez, A Italiano, G Curigliano, M Javle, F de Braud, GW Prager, R Greil, A Stein, A Fasolo, JHM Schellens, PY Wen, K Viele, AD Boran, E Gasal, P Burgess, P Ilankumaran, ZA Wainberg

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading

Most Read This Week

Recently Updated